Postpartum Depression Can Be ID'd During Infant Hospitalization

This article originally appeared here.
Share this content:
Postpartum Depression Can Be ID'd During Infant Hospitalization
Postpartum Depression Can Be ID'd During Infant Hospitalization

MONDAY, Aug. 22, 2016 (HealthDay News) -- Postpartum depression screening conducted during infant hospitalization can identify depression among previously unscreened women, according to a study published online Aug. 16 in the Journal of Hospital Medicine.

Margaret J. Trost, M.D., from the Children's Hospital Los Angeles, and colleagues assessed postpartum depression at infant hospitalization in a prospective study conducted among 310 women with an infant aged 2 weeks to 1 year who were admitted to a pediatric hospitalist service. Mothers completed demographic questionnaires, a maternal-infant bonding scale, and the Edinburgh Postpartum Depression Scale (EPDS). Those with a positive screen on the EPDS received counseling and mental health referrals.

The researchers found that 28 percent of mothers were positive on the EPDS. Appropriate prior depression screening was reported by 14.6 percent. Poor social support and history of psychiatric diagnoses were maternal factors associated with being EPDS+ (odds ratios, 4.40 and 5.02, respectively); there was a correlation for having an infant with neurodevelopmental comorbidities with EPDS+ screens (odds ratio, 2.78). Of the 21 initially EPDS+ mothers who were reached by phone, 38 percent used their doctor or referral resource, resulting in lower EPDS scores versus those not seeking help (P < 0.05).

"Postpartum depression screening during infant hospitalizations captures women previously unscreened," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »